Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

NCT06825845 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

1500

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: Zevorcabtagene Autoleucel

Sponsor

CARsgen Therapeutics Co., Ltd.